Furthermore, the VAPB-PTPIP51 interaction may have broader implications in neurodegenerative diseases, as Liu et al recently demonstrated that α-synuclein can modulate VAPB-PTPIP51 binding, potentially linking this pathway to Parkinson’s disease (Liu et al, 2025). Here, RMDN3 is linked to Parkinson disease.